+44 20 8123 2220
info@marketpublishers.com

Artificial Intelligence For Drug Development and Discovery Market by Type (Target Identification, Molecule Screening, De Novo Drug Design & Drug Optimization, and Preclinical & Clinical Testing), Indication, (Oncology, Neurology, Infectious Disease and Others), and End User (Pharmaceutical & Biotechnology Companies, and Contract Research Organization): Global Opportunity Analysis and Industry Forecast, 2019–2027

https://marketpublishers.com/r/A273BFE9066FEN.html
Date: June 2020
Pages: 210
Price: US$ 5,769.00 (Single User License)
ID: A273BFE9066FEN

Abstracts

The artificial intelligence for drug discovery and development market was valued at $520 million in 2019 and is projected to reach $4,815 million by 2027, registering a CAGR of 31.6% from 2020 to 2027.

Artificial intelligence (AI) is science and engineering adopted to design intelligent machines, especially intelligent computer programs. AI is an intelligent system that relates various human intelligence based functions such as reasoning, learning, and problem-solving skills on different disciplines such as biology, computer science, psychology, mathematics, linguistics, and engineering. In the healthcare industry, AI is applicable in medication management, treatment plans, drug discovery& developments and others.

Drug discovery& development includes several processes and phases that demand a huge amount of funds. Furthermore, clinical trials and approval of the drug in the market might be a challenging task. Increase in number of collaborations between pharmaceutical & biotech companies and AI providers are the major driver for this

+44 20 8123 2220
info@marketpublishers.com

market. Artificial intelligence decreases a large amount of time and cost utilized in the drug discovery and development process, which is mainly influencing the market growth. The increasing demand for cloud-based software that enables the researcher to design drugs quickly and accurately is expected to drive the market growth. Moreover, the integration of artificial intelligence (AI) and machine learning approaches within the life science R&D industry is making drug discovery and development more innovative, time-effective and cost-effective.

The artificial intelligence for drug discovery and development market is segmented on the type, indication, end user and region. By type, it is divided into target identification, molecules screening, de novo drug design &drug optimization and preclinical &clinical testing. On the basis of indication, it is classified into oncology, infectious disease, neurology, and others. By end user, it is segmented into pharmaceutical & biotechnology companies, and CROs.

Region wise, the market is analyzed across North America (US, Canada), Europe (Germany, France, UK, Rest of Europe), Asia-Pacific (Japan, China, Australia, India, Rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).North America held the major share of the artificial intelligence for drug discovery and development market in 2019 and is expected to continue its dominance during the forecast period, owing to strong economies in the U.S. and Canada; high adoption rate of AI technologies due to large number of investments to boost the drug discovery industry; and large number of cross industry collaborations and partnerships majorly fuels the market growth. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to rise in adoption of advanced AI technologies, and growth in focus of major players on increasing their presence in emerging Asian countries.

KEY MARKET SEGMENTS

By Type

Target Identification

Molecule Screening

De Novo Drug Design and Drug Optimization

Preclinical and Clinical Testing

+44 20 8123 2220
info@marketpublishers.com

By Indication

- Oncology
- Infectious Disease
- Neurology
- Others

By End User

- Pharmaceutical and Biotechnology Companies.
- Contract Research Organization (CROs).

By Geography

- North America
  - U.S.
  - Canada
- Europe
  - Germany
  - France
  - UK
  - Rest of Europe
- Asia Pacific

+44 20 8123 2220
info@marketpublishers.com

- Japan
- China
- India
- Australia
- Rest of Asia-Pacific

LAMEA

- Latin America
- Middle East & Africa

LIST OF KEY PLAYERS PROFILED IN THE REPORT

- Alphabet Inc.
- Atomwise, Inc
- Benevolent AI
- Cloud Pharmaceutical
- Deep Genomics
- Exscientia
- Insilico Medicine Inc.
- Microsoft Corporation
- Nvidia Corporation

+44 20 8123 2220
info@marketpublishers.com

Contents

CHAPTER 1: INTRODUCTION

1.1. Report description
1.1. Key benefits for stakeholders
1.2. Key market segments
  1.2.1. List of key players profiled in the report
1.3. Research methodology
  1.3.1. Secondary research
  1.3.2. Primary research
  1.3.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
  3.2.1. Top investment pockets
  3.2.2. Top winning strategies
3.3. Top player positioning, 2019
3.4. Porter’s five forces analysis
3.5. Market dynamics
  3.5.1. Drivers
    3.5.1.1. Growing number of cross industry collaborations and partnerships
    3.5.1.2. Artificial intelligence reduces cost and time utilized in the drug discovery& development process.
  3.5.2. Restraints
    3.5.2.1. Lack of skilled professionals
    3.5.2.2. Lack of data sets in the field of drug discovery
  3.5.3. Opportunity
    3.5.3.1. Increase in awareness related to artificial intelligence
    3.5.3.2. Untapped market in developing regions
  3.5.4. Impact Analysis

CHAPTER 4: ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND

+44 20 8123 2220
info@marketpublishers.com

DEVELOPMENT MARKET, BY TYPE

4.1. Overview
4.1.1. Market size and forecast
4.2. Target Identification
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Molecule Screening
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. De Novo Drug Design and Drug Optimization
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Preclinical and clinical testing
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

CHAPTER 5: ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET, BY INDICATION

5.1. Overview
5.1.1. Market size and forecast
5.2. Oncology
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Neurology
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Infectious Disease
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Others
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country

+44 20 8123 2220
info@marketpublishers.com

CHAPTER 6: ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT, BY END USER

6.1. Overview
6.1.1. Market size and forecast
6.2. Pharmaceutical and biotechnology companies
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Contract Research Organization
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

CHAPTER 7: GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET, BY REGION

7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. North America artificial intelligence for drug discovery and development , by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. artificial intelligence for drug discovery and development market, by type
7.2.2.1.2. U.S artificial intelligence for drug discovery and development market, by indication
7.2.2.1.3. U.S. artificial intelligence for drug discovery and development market, by end user
7.2.2.2. Canada
7.2.2.2.1. Canada artificial intelligence for drug discovery and development market, by type
7.2.2.2.2. Canada artificial intelligence for drug discovery and development market, by indication
7.2.2.2.3. Canada artificial intelligence for drug discovery and development market, by end user
7.2.3. North America artificial intelligence for drug discovery and development market, by type
7.2.4. North America artificial intelligence for drug discovery and development , by indication

+44 20 8123 2220
info@marketpublishers.com

7.2.5. North America artificial intelligence for drug discovery and development , by end user
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Europe artificial intelligence for drug discovery and development , by country
7.3.2.1. UK artificial intelligence for drug discovery and development market, by type
7.3.2.1.1. UK artificial intelligence for drug discovery and development market, by type
7.3.2.1.2. UK artificial intelligence for drug discovery and development market, by indication
7.3.2.1.3. UK artificial intelligence for drug discovery and development market, by end user
7.3.2.2. Germany
7.3.2.2.1. Germany artificial intelligence for drug discovery and development market, by type
7.3.2.2.2. Germany artificial intelligence for drug discovery and development market, by indication
7.3.2.2.3. Germany artificial intelligence for drug discovery and development market, by end user
7.3.2.3. France
7.3.2.3.1. France artificial intelligence for drug discovery and development market, by type
7.3.2.3.2. France artificial intelligence for drug discovery and development market, by indication
7.3.2.3.3. France artificial intelligence for drug discovery and development market, by end user
7.3.2.4. Rest of Europe
7.3.2.4.1. Rest of Europe artificial intelligence for drug discovery and development market, by type
7.3.2.4.2. Rest of Europe artificial intelligence for drug discovery and development market, by indication
7.3.2.4.3. Rest of Europe artificial intelligence for drug discovery and development market, by end user
7.3.3. Europe artificial intelligence for drug discovery and development , by type
7.3.4. Europe artificial intelligence for drug discovery and development , by indication
7.3.5. Europe artificial intelligence for drug discovery and development , by end user
7.4. Asia-pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Asia-Pacific artificial intelligence for drug discovery and development , by

+44 20 8123 2220
info@marketpublishers.com

country
7.4.2.1. Japan
7.4.2.1.1. Japan artificial intelligence for drug discovery and development market, by type
7.4.2.1.2. Japan artificial intelligence for drug discovery and development market, by indication
7.4.2.1.3. Japan artificial intelligence for drug discovery and development market, by end user
7.4.2.2. China
7.4.2.2.1. China artificial intelligence for drug discovery and development market, by type
7.4.2.2.2. China artificial intelligence for drug discovery and development market, by indication
7.4.2.2.3. China artificial intelligence for drug discovery and development market, by end user
7.4.2.3. Australia
7.4.2.3.1. .Australia artificial intelligence for drug discovery and development market, by type
7.4.2.3.2. Australia artificial intelligence for drug discovery and development market, by indication
7.4.2.3.3. Australia artificial intelligence for drug discovery and development market, by end user
7.4.2.4. India
7.4.2.4.1. India artificial intelligence for drug discovery and development market, by type
7.4.2.4.2. India artificial intelligence for drug discovery and development market, by indication
7.4.2.4.3. India artificial intelligence for drug discovery and development market, by end user
7.4.2.5. Rest of Asia-Pacific
7.4.2.5.1. Rest of Asia-Pacific artificial intelligence for drug discovery and development market, by type
7.4.2.5.2. Rest of Asia-Pacific artificial intelligence for drug discovery and development market, by indication
7.4.2.5.3. Rest of Asia-Pacific artificial intelligence for drug discovery and development market, by end user
7.4.3. Asia-Pacific artificial intelligence for drug discovery and development , by type
7.4.4. Asia-Pacific artificial intelligence for drug discovery and development , by indication

+44 20 8123 2220
info@marketpublishers.com

7.4.5. Asia-Pacific artificial intelligence for drug discovery and development , by end user
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. LAMEA artificial intelligence for drug discovery and development , by country
7.5.2.1. Latin America
7.5.2.1.1. Latin America artificial intelligence for drug discovery and development market, by type
7.5.2.1.2. Latin America artificial intelligence for drug discovery and development market, by indication
7.5.2.1.3. Latin America artificial intelligence for drug discovery and development market, by end user
7.5.2.2. Middle east and Africa
7.5.2.2.1. Middle east and Africa artificial intelligence for drug discovery and development market, by type
7.5.2.2.2. Middle east and Africa artificial intelligence for drug discovery and development market, by indication
7.5.2.2.3. Middle east and Africa artificial intelligence for drug discovery and development market, by end user

CHAPTER 8: COMPANY PROFILES

8.1. ALPHABET INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. ATOMWISE, INC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segment
8.2.4. Product portfolio
8.2.5. Key strategic moves and developments
8.3. BENEVOLENT AI
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segment
8.3.4. Product portfolio

+44 20 8123 2220
info@marketpublishers.com

8.3.5. Key strategic moves and developments
8.4. CLOUD PHARMACEUTICAL
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segment
8.4.4. Product portfolio
8.4.5. Key strategic moves and developments
8.5. DEEP GENOMICS
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segment
8.5.4. Product portfolio
8.6. EXSCIENTIA.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segment
8.6.4. Product portfolio
8.6.5. Key strategic moves and developments
8.7. IBM CORPORATION
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. INSILICO MEDICINE INC.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segment
8.8.4. Product portfolio
8.8.5. Key strategic moves and developments
8.9. MICROSOFT CORPORATION
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. NVIDIA CORPORATION

+44 20 8123 2220
info@marketpublishers.com

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

TABLE 01. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 02. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET FORTARGET IDENTIFICATION, BY REGION, 2019–2027 ($MILLION)
TABLE 03. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET FOR MOLECULE SCREENING, BY REGION, 2019–2027 ($MILLION)
TABLE 04. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET FORDE NOVO DRUG DESIGN AND DRUG OPTIMIZATION, BY REGION, 2019–2027 ($MILLION)
TABLE 05. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET FOR DE NOVO DRUG DESIGN AND DRUG OPTIMIZATION, BY REGION, 2019–2027 ($MILLION)
TABLE 06. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET, BY INDICATION, 2019–2027($MILLION)
TABLE 07. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET REVENUE, BY ONCOLOGY, 2019–2027 ($MILLION)
TABLE 08. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET REVENUE, BY NEUROLOGY, 2019–2027 ($MILLION)
TABLE 09. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET REVENUE, BY INFECTIOUS DISEASE, 2019–2027 ($MILLION)
TABLE 10. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET REVENUE, BY OTHERS, 2019–2027 ($MILLION)
TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2019–2027 ($MILLION)
TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY CONTRACT RESEARCH ORGANIZATION, 2019–2027 ($MILLION)
TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 15. NORTH AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY COUNTRY, 2019-2027 ($MILLION)

+44 20 8123 2220
info@marketpublishers.com

TABLE 16. U.S. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 17. U.S. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 18. U.S. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT, BY END USER, 2019-2027 ($MILLION)
TABLE 19. CANADA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 20. CANADA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 21. CANADA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 22. NORTH AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 23. NORTH AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 24. NORTH AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 25. EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY COUNTRY, 2019-2027 ($MILLION)
TABLE 26. UK ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 27. UK ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 28. UK ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 29. GERMANY ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 30. GERMANY ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 31. GERMANY ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 32. FRANCE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 33. FRANCE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 34. FRANCE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 35. REST OF EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY

+44 20 8123 2220
info@marketpublishers.com

AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 36. REST OF EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 37. REST OF EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 38. EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 39. EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 40. EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 41. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY COUNTRY, 2019-2027 ($MILLION)
TABLE 42. JAPAN ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 43. JAPAN ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 44. JAPAN ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 45. CHINA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 46. CHINA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 47. CHINA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 48. AUSTRALIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 49. AUSTRALIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 50. AUSTRALIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 51. INDIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 52. INDIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 53. INDIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 54. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)

+44 20 8123 2220
info@marketpublishers.com

TABLE 55. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 56. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 57. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 58. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 59. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 60. LAMEA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY COUNTRY, 2019-2027 ($MILLION)
TABLE 61. LATIN AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 62. LATIN AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 63. LATIN AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 64. MIDDLE EAST AND AFRICAARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 65. MIDDLE EAST AND AFRICAARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 66. MIDDLE EAST AND AFRICAARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 67. ALPHABET INC.: COMPANY SNAPSHOT
TABLE 68. ALPHABET INC.: OPERATING SEGMENTS
TABLE 69. ALPHABET INC.: PRODUCT PORTFOLIO
TABLE 70. ATOMWISE: COMPANY SNAPSHOT
TABLE 71. ATOMWISE: PRODUCT PORTFOLIO
TABLE 72. BENEVOLENT: COMPANY SNAPSHOT
TABLE 73. BENEVOLENT: PRODUCT PORTFOLIO
TABLE 74. CLOUD: COMPANY SNAPSHOT
TABLE 75. CLOUD: PRODUCT PORTFOLIO
TABLE 76. DEEP: COMPANY SNAPSHOT
TABLE 77. DEEP: PRODUCT PORTFOLIO
TABLE 78. EXSCIENTIA: COMPANY SNAPSHOT
TABLE 79. EXSCIENTIA: PRODUCT PORTFOLIO
TABLE 80. IBM CORPORATION: COMPANY SNAPSHOT
TABLE 81. IBM: OPERATING SEGMENTS

+44 20 8123 2220
info@marketpublishers.com

TABLE 82. IBM: PRODUCT PORTFOLIO
TABLE 83. INSILICO: COMPANY SNAPSHOT
TABLE 84. INSILICO: PRODUCT PORTFOLIO
TABLE 85. MICROSOFT CORPORATION: COMPANY SNAPSHOT
TABLE 86. MICROSOFT CORPORATION: OPERATING SEGMENTS
TABLE 87. MICROSOFT: PRODUCT PORTFOLIO
TABLE 88. NVIDIA: COMPANY SNAPSHOT
TABLE 89. NVIDIA: OPERATING SEGMENTS
TABLE 90. NVIDIA: PRODUCT PORTFOLIO

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

FIGURE 01. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2017–2020*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017–2020* (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2017–2020*
FIGURE 06. TOP PLAYER POSITIONING, 2019
FIGURE 07. MODERATE BARGANING POWER OF SUPPLIER
FIGURE 08. MODERATE BARGAINING POWER OF BUYERS
FIGURE 09. LOW THREAT OF NEW ENTRANT
FIGURE 10. LOW THREAT OF SUBSTITUTION
FIGURE 11. HIGH COMPETITIVE RIVALRY
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. COMPARATIVE ANALYSIS OF ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET, FOR TARGET IDENTIFICATIONBY COUNTRY, 2019 & 2027(%)
FIGURE 14. COMPARATIVE ANALYSIS OF ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET, FOR MOLECULE SCREENINGBY COUNTRY, 2019 &2027 (%)
FIGURE 15. COMPARATIVE ANALYSIS OF ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET, FOR DE NOVO DRUG DESIGN AND DRUG OPTIMIZATION BY COUNTRY, 2019 &2027(%)
FIGURE 16. COMPARATIVE ANALYSIS OF ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET, FOR DE NOVO DRUG DESIGN AND DRUG OPTIMIZATION BY COUNTRY, 2019 &2027(%)
FIGURE 17. COMPARATIVE ANALYSIS OF ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET, FOR ONCOLOGYBY COUNTRY, 2019 & 2027 (%)
FIGURE 18. COMPARATIVE ANALYSIS OF ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET, FOR NEUROLOGY BY COUNTRY, 2019 & 2027 (%)
FIGURE 19. COMPARATIVE ANALYSIS OF ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET, FOR INFECTIOUS DISEASEBY COUNTRY, 2019 & 2027 (%)
FIGURE 20. COMPARATIVE ANALYSIS OF ARTIFICIAL INTELLIGENCE FOR DRUG

+44 20 8123 2220
info@marketpublishers.com

DISCOVERY AND DEVELOPMENTMARKET, FOR OTHERSBY COUNTRY, 2019 & 2027 (%)
FIGURE 21. COMPARATIVE ANALYSIS OF ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET, FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIESBY COUNTRY, 2019 & 2027 (%)
FIGURE 22. COMPARATIVE ANALYSIS OF ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET, FOR CONTRACT RESEARCH ORGANIZATION BY COUNTRY, 2019 & 2027 (%)
FIGURE 23. ALPHABET INC.: REVENUE, 20187–2019 ($MILLION)
FIGURE 24. ALPHABET INC.: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 25. ALPHABET INC.: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 26. IBM: REVENUE, 2017–2019 ($MILLION)
FIGURE 27. IBM: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 28. IBM: REVENUE SHARE BY REGION 2019 (%)
FIGURE 29. MICROSOFT CORPORATION: REVENUE, 2017–2019 ($MILLION)
FIGURE 30. MICROSOFT CORPORATION: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 31. MICROSOFT CORPORATION: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 32. NVIDIA: REVENUE, 2018–2020 ($MILLION)
FIGURE 33. NVIDIA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34. NVIDIA: REVENUE SHARE BY REGION, 2020 (%)

COMPANIES MENTIONED

Alphabet Inc., Atomwise, Inc., Benevolent AI, Cloud Pharmaceutical, Deep Genomics, Exscientia, IBM Corporation, Insilico Medicine Inc., Microsoft Corporation, and Nvidia Corporation

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Artificial Intelligence For Drug Development and Discovery Market by Type (Target Identification, Molecule Screening, De Novo Drug Design & Drug Optimization, and Preclinical & Clinical Testing), Indication, (Oncology, Neurology, Infectious Disease and Others), and End User (Pharmaceutical & Biotechnology Companies, and Contract Research Organization): Global Opportunity Analysis and Industry Forecast, 2019–2027

Product link: https://marketpublishers.com/r/A273BFE9066FEN.html

Price: US$ 5,769.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/A273BFE9066FEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

+44 20 8123 2220
info@marketpublishers.com

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970